AbbVie Stock News Today (Dec. 22, 2025): ABBV Holds Near $227 as Drug-Pricing Talks, Dividend Growth, and 2026 Catalysts Come Into Focus
AbbVie Inc. (NYSE: ABBV) is trading near recent highs on Monday, December 22, 2025, as investors weigh a powerful mix of policy risk, shareholder returns, and pipeline momentum heading into 2026. The big near-term variable isn’t a clinical readout—it’s Washington. After the White House unveiled sweeping “most-favored-nation” (MFN) drug-pricing agreements with nine large manufacturers on December 19, AbbVie remains one of the last major drugmakers still outside the deal. The White House+1 At the same time, AbbVie’s core fundamentals continue to be anchored by its immunology franchise—Skyrizi and Rinvoq—alongside a rising dividend profile and a pipeline that includes late-stage programs